Cyp4f39 Inhibitors
Cyp4f39 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Cyp4f39 enzyme, a member of the cytochrome P450 superfamily. The Cyp4f39 enzyme plays a critical role in the metabolism of various lipophilic substrates, particularly long-chain fatty acids and eicosanoids, which are bioactive lipids involved in signaling pathways that regulate inflammation, vascular tone, and other physiological processes. The primary function of Cyp4f39 is to catalyze the hydroxylation of these substrates, a biochemical reaction that introduces an oxygen atom into the lipid molecule. This hydroxylation process typically enhances the solubility of these lipids, facilitating their subsequent metabolism, conjugation, or excretion from the body. Cyp4f39 is mainly expressed in tissues like the liver and kidneys, where it contributes to the detoxification and metabolic regulation of bioactive lipids, thus playing a significant role in maintaining homeostasis.
Inhibitors of Cyp4f39 are generally small molecules designed to bind to the enzyme's active site, effectively preventing it from catalyzing the hydroxylation of its natural substrates. These inhibitors may function by occupying the substrate-binding pocket, blocking the access of substrates to the catalytic core, or by inducing conformational changes that decrease the enzyme's catalytic efficiency. The development of Cyp4f39 inhibitors involves detailed structural analysis to identify the key regions responsible for substrate recognition and catalytic activity. By inhibiting Cyp4f39, researchers can investigate the specific role of this enzyme in lipid metabolism and its broader impact on related metabolic pathways, particularly those involved in the regulation of inflammation and vascular function. The study of Cyp4f39 inhibitors is essential for understanding the enzyme's substrate specificity, its interactions with other enzymes in lipid metabolic networks, and its overall contribution to the complex regulatory processes that maintain lipid homeostasis in the body. This research provides valuable insights into the functional diversity of cytochrome P450 enzymes and underscores their importance in regulating key biochemical pathways essential for health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1-Aminobenzotriazole | 1614-12-6 | sc-200600 sc-200600A | 50 mg 100 mg | $60.00 $131.00 | 6 | |
1-Aminobenzotriazole acts as a direct inhibitor of Cyp4f39 by binding to its active site, disrupting the enzyme's catalytic function in the metabolism of fatty acids. This leads to a targeted inhibition of the protein, hindering its role in lipid homeostasis within various physiological structures. | ||||||
Sulconazole | 61318-90-9 | sc-338599 | 100 mg | $1000.00 | 1 | |
Sulconazole serves as a direct inhibitor of Cyp4f39, interfering with its heme group and thereby suppressing its role in the metabolism of arachidonic acid. This results in a specific inhibition of the protein, impacting its diverse expression in critical systems, including the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $41.00 $56.00 | 6 | |
Clotrimazole acts as a direct inhibitor of Cyp4f39 by binding to its heme group, disrupting the enzyme's catalytic function in the metabolism of fatty acids. This leads to a specific inhibition of the target protein, influencing its expression within the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, impacting lipid homeostasis. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $65.00 $157.00 | 2 | |
Miconazole functions as a direct inhibitor of Cyp4f39, binding to its heme group and interfering with the enzyme's catalytic function in the metabolism of fatty acids. This results in a targeted inhibition of the protein, affecting its diverse expression across critical physiological structures, including the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems. | ||||||
Econazole | 27220-47-9 | sc-279013 | 5 g | $240.00 | ||
Econazole acts as a direct inhibitor of Cyp4f39 by disrupting the enzyme's heme group, hindering its catalytic activity in the metabolism of arachidonic acid. This leads to a specific inhibition of the protein, influencing its expression in various physiological structures such as the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, impacting lipid homeostasis. | ||||||
Imidazole | 288-32-4 | sc-204776 sc-204776A sc-204776B sc-204776C | 25 g 100 g 1 kg 5 kg | $26.00 $55.00 $82.00 $336.00 | 2 | |
Imidazole acts as an indirect inhibitor of Cyp4f39 by influencing the PI3K/Akt signaling pathway. Through this modulation, the chemical disrupts the cellular processes that regulate the protein's activity, impacting its expression in critical physiological structures like the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, thereby influencing lipid homeostasis. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine serves as a direct inhibitor of Cyp4f39, disrupting the enzyme's heme group and impeding its catalytic activity in the metabolism of arachidonic acid. This leads to a specific inhibition of the protein, impacting its expression in diverse physiological structures, including the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, influencing lipid homeostasis. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Fluconazole serves as a direct inhibitor of Cyp4f39 by disrupting the enzyme's heme group, hindering its catalytic activity in the metabolism of arachidonic acid. This leads to a specific inhibition of the protein, influencing its expression in various physiological structures, such as the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, impacting lipid homeostasis. | ||||||
4-Methylumbelliferone | 90-33-5 | sc-206910 sc-206910A sc-206910B sc-206910C sc-206910D | 25 g 100 g 250 g 1 kg 2.5 kg | $34.00 $55.00 $138.00 $423.00 $954.00 | 2 | |
Methylumbelliferone indirectly inhibits Cyp4f39 by altering the expression of key genes in the xenobiotic metabolism pathway. This chemical interferes with the enzyme's substrate availability, impeding its catalytic activity. The altered substrate availability impacts the protein's expression in various physiological structures, including the cardiovascular, central nervous, endocrine, genitourinary, and digestive systems, influencing lipid homeostasis. | ||||||